

## Agenda

Annual General Meeting of the  
Melanoma Network of New Zealand Incorporated

2.10 pm Saturday 11 May 2024  
Conway Rooms, Te Pae Convention Centre, Christchurch

1. Welcome, apologies and proxies
2. Draft minutes of 28 November 2023 Annual General Meeting
3. Report of the Executive Committee Co-Chairs
4. Statement of receipts and payments for the 2023 Financial Year (Jan – Dec)
5. Presentation of conflicts of interest declared by Officers
6. Remits
  - a. Resolution that Chris Boberg and Richard Massey be eligible for re-election
7. Election of Executive Committee
8. General discussion
9. Acknowledgements and closing

### **Objectives of the Melanoma Network of New Zealand Incorporated**

- To facilitate communication and collaboration between professionals with a commitment to reducing the incidence and impact of melanoma in New Zealand.
- To promote education and the advancement of best practice among professionals working in melanoma.

**Draft Minutes of the Annual General Meeting of the  
Melanoma Network of New Zealand Incorporated (MelNet)  
Zoom videoconference  
7.40 – 8.10 pm Tuesday 28 November 2023**

Members Present:

Gary Duncan (Meeting Chair), Chris Boberg, Jody Jordan, Amanda Oakley, Richard Massey, Bronwen McNoe, Abbie Cameron, Brandon Adams, Dan Butler, Susan Seifried, Katy Doherty, Michael Zheng, Victoria Muir, Marion Peat, Katrina Patterson (CEO and minute taker)

Apologies:

Richard Martin, Annie Wong

**1. Welcome, apologies and proxies**

Gary Duncan, Co-Chair of the Executive Committee, welcomed those present to the Annual General Meeting of MelNet. Apologies were noted. There were no proxies.

**2. Draft minutes of 4 November 2022 Annual General Meeting**

The draft minutes of the 4 November 2022 meeting were approved. (Moved: Gary Duncan, seconded: Jody Jordan, Approved: All). There were no matters arising.

**3. Report of the Executive Committee Chair**

Gary Duncan, Meeting Chair, spoke to the circulated report of the Executive Committee Chair.

Susan Seifried, Chair National Melanoma Working Group, updated meeting attendees on the status of the Quality Statement to Guide Melanoma Diagnosis and Treatment in New Zealand, noting:

- The Cancer Control Agency have withdrawn their endorsement of the Quality Statements as they are unable to formally endorse documents they don't have full control over.
- The Cancer Control Agency remain supportive of the Quality Statements as an up-to-date guide to best practice and an important educational tool. They have agreed to provide wording that expresses this support in lieu of endorsement.
- The Cancer Control Agency have agreed to support MelNet's engagement with Health NZ on the implementation of the Quality Statements.
- MelNet will continue to work with the Cancer Control Agency on the development of Quality Performance Indicators and Optimal Cancer Care Pathways.

Gary thanked Susan for her leadership of this work.

The report presented was approved (Moved: Gary Duncan, Seconded: Chris Boberg, Approved: All).

**4. Statement of Accounts**

The statement of accounts for the period 1 January to 31 December 2022 was presented.

The Meeting Chair noted that MelNet ad managed to generate sufficient income from educational events to remain solvent, but is still without a guaranteed source of income.

Over the past two years, MelNet and Melanoma New Zealand have tried to broker a formal partnership, however the MelNet Executive Committee was not amenable to the proposal put forward by Melanoma NZ. MelNet and Melanoma NZ will continue to work collaboratively, but there are no ongoing discussions about financial support.

Discussions with Government agencies about potential funding pathways are ongoing.

The accounts presented were approved. (Moved: Jody Jordan, Seconded: Bronwen McNoe, Approved: All).

## **5. Remits**

Remit A: The Meeting Chair spoke to the circulated remit seeking changes to the Rules to comply with the Incorporated Societies Act 2022.

The remit was accepted (Moved: Gary Duncan, Seconded: Abbie Cameron, Approved: All)

Remit B: Chris Boberg spoke to the circulated remit requesting that Gary Duncan and Richard Martin be eligible for re-election to the 2023/24 Executive Committee.

The remit was accepted (Moved: Chris Boberg, Seconded: Jody Jordan, Approved: All)

## **6. Election of Executive Committee**

The Meeting Chair spoke to the circulated document *Introducing the MelNet Executive Committee Members and Candidates for 2023/2024*. As outlined, members are elected for a two-year term; those to serve the second year of their term without requiring election were Amanda Oakley, Annie Wong, Chris Boberg, Richard Massey, Susan Seifried and Megan Chapman.

The Meeting Chair explained that five candidates had been nominated for election by 5.00 pm on 15 November (the deadline required by the Rules). Those nominated were Abbie Cameron, Bronwen McNoe, Gary Duncan, Richard Martin and Jody Jordan.

All five candidates were approved. (Moved: Gary Duncan, Seconded: Richard Massey, Approved: All).

## **7. Discussion paper – Non-Melanoma Skin Cancer**

The Meeting Chair spoke to the circulated document *Inclusion of Non-Melanoma Skin Cancer in MelNet's scope of work*. Attendees agreed that it was sensible for MelNet to include non-melanoma skin cancer in its remit and that the Executive Committee should explore how to go forward with this.

## **8. Acknowledgements and Closing**

The Meeting Chair acknowledged the enormous contribution of Amanda Oakley, whose courses generated much of MelNet's income this year. He also thanked the operational team for their continued efforts.

Finally, he thanked members for attending as well as the wider membership for their continued passion and dedication.

Chris Boberg thanked the Meeting Chair for all his hard work.

The meeting closed at 8.10 pm.

# Report of the Executive Committee Chair to the Annual General Meeting of the Melanoma Network of New Zealand Incorporated

1 May 2024

With it being only five months since our last AGM, there is less to report at this AGM than usual.

We are pleased to advise that MelNet has successfully re-registered as an Incorporated Society under the new Incorporated Societies Act 2022. To meet our obligations under this Act, MelNet's AGM will now be held before 30 June each year.

## **Building the capability of our healthcare workforce**

2024 is shaping up to be another successful year for MelNet.

Much of our resource in this first part of the year has been dedicated to organising the Melanoma Mini-Summit. While concerns of financial loss meant we were not able to host a full two-day Summit, we have still endeavoured to provide the New Zealand melanoma community with an opportunity to come together to share and discuss latest developments across the spectrum of melanoma management. We are proud of the programme we have put together, which showcases New Zealand research, promotes best practice and supports our objectives to improve melanoma prevention, early detection and ensure all those who develop melanoma in New Zealand receive the best quality care. We thank those who have given their time to participate in this important event, particularly our presenters who have traveled from around the country. Special thanks must go to Professor David Whiteman who has come from Australia to share his considerable expertise, and who continues to be a staunch ally for improving skin cancer prevention and early detection in New Zealand. Organising an event like this is no small task, and we acknowledge the efforts of our operational team – Katrina Patterson and Marion Peat – for their hard work.

We express our sincere thanks to Amanda Oakley, who so far this year has presented two beginner Skin Lesion and Dermoscopy courses on behalf of MelNet – the first as part of the Goodfellow Symposium in March and the second as a Pre-Summit workshop to this event. These courses are an excellent and affordable way for healthcare practitioners to undertake basic training in the identification of typical benign and malignant skin lesions and are also a vital source of income for our organisation.

## **Championing best practice melanoma care through the Quality Statements**

Since the last AGM, MelNet Executive Committee members have met with leaders of the Cancer Control Agency to discuss the withdrawal of their support for the *Quality Statements*.

We have been advised that this withdrawal is due to a change in internal policies which no longer permit the endorsement or support of work completed by external agencies. This position is difficult to understand.

Despite this, the Agency has expressed support for the *Quality Statements* which they felt represent the standard of care we should be working towards for melanoma patients in New Zealand. They have committed to drafting a statement to this effect which will be included in the document and have offered to facilitate engagement with Health New Zealand to ensure current practice continues to move towards the standard outlined in the *Quality Statements*. While these outcomes have not yet come to fruition, we will continue to work with the Agency to achieve this.

The Agency has also confirmed that the *Quality Statements* will be used as a foundation to develop melanoma models of care – particularly Optimal Cancer Care Pathways. This work is scheduled to commence mid-year.

The next formal review of the *Quality Statements* will take place in 2025, however we encourage feedback at any time to our Chief Executive.

### **Advocating for improved primary prevention and early detection in New Zealand**

Over the past year, representatives from the MelNet Executive Committee have been actively advocating to Health New Zealand for increased investment in skin cancer primary prevention and early detection.

We have been pleased to see an increased level of interest in this area by Health NZ, and can report we have been commissioned to deliver an updated New Zealand Skin Cancer Primary Prevention and Early Detection Strategy.

With the updated document due by the end of June, we have brought together a small group of experts to review the content and will be circulating a draft document widely for consultation.

We hope this updated document will provide a strong case for significant and ongoing investment into interventions that support improved skin cancer prevention and early detection activities.

### **Providing opportunities for connection and professional collaboration**

2024 will bring the establishment of a new Special Interest Group. This group, supported by MelNet will be targeted at nurses with a specific interest in skin cancer.

The purpose of the group will be to grow the number of nurses working in skin cancer, support and facilitate ongoing professional development, provide a platform for discussion and collaboration, and promote the exchange of knowledge and best practice.

Nurses are playing an increasingly active role in the prevention, detection and management of skin cancer, and while still in its infancy, we are excited about the prospects of this group. Thank you to Abbie Cameron for her work in driving this forward.

### **Advocating for improved pathology services**

Much of our advocacy last year focused on improving funding and resources for pathology services. While this work has continued into 2024, we are disappointed to report that little progress has been made.

Health New Zealand Auckland is continuing its work to ensure the Anatomical Pathology Service has adequate facilities and staffing to cope with demand. Additional temporary laboratory facilities are expected to be in place by August, with a longer-term plan to build and staff an expanded facility running in parallel.

While we were assured that MelNet would be consulted on the development of a new service model for pathology services in Auckland, to date, we have received no communication regarding this. We will endeavour to meet with Health NZ officials who oversee this work to better understand the process and where MelNet can input.

### **Looking forward to the remainder of the year**

The remainder of the year will see MelNet deliver another Skin Cancer Study Day for Nurses, scheduled for 1 November in Auckland. A comprehensive skin cancer programme will also be presented at GPCME North meeting in June. We are grateful to the presenters who are giving their time to share their expertise at these events.

While 2024 so far has been more profitable than past years, MelNet remains without a reliable and ongoing income source. To ensure the ongoing viability of our organisation, we will be focusing much of our resource for the latter half of the year on working to secure funding that can help sustain our organisation now and grow it into the future.

The Executive will also look to develop a remit to present at the next AGM to formally amend the objects in MelNet's constitution to cover both melanoma and non-melanoma skin cancer, and review and update MelNet's current strategic plan to align with this change in scope. This concept was supported by the membership at last year's AGM.

## **Acknowledgments**

We are incredibly grateful for our partners who have supported our organisation so far this year – Aotearoa Gaming Trust, MSD, La-Roche Posay, Goodfellow, Skin Cancer Symposiums, NZ Skin Cancer Doctors Society, Reform Radiology and HealthBox. It is with this support that we can deliver what we do.

We would like to thank members of the Executive Committee for the commitment, skill and guidance they continue to bring to the organisation. We express our appreciation to Megan Chapman who will be stepping down from the Committee this year after many years of service. Megan has had considerable input into the work of the organisation and has been instrumental in guiding our partnership with the Health Promotion Agency.

Finally, to our members. Thank you for your unwavering commitment to reducing the incidence and impact of skin cancer in New Zealand. We look forward to your ongoing active involvement in our organisation.

Gary Duncan and Chris Boberg  
Co-Chairs, Executive Committee  
Melanoma Network of New Zealand Inc

# Melanoma Network of New Zealand Incorporated

## Statement of Receipts and Payments

For the year ended:  
31 December 2023

	Notes	Actual This Year \$	Actual Last Year \$
<b>Operating Receipts</b>			
Donations, fundraising and other similar receipts		6,838	24,695
Receipts from providing goods or services	2.1	89,952	107,026
Refund of payments for goods or services (Summit)	2.3	-	(22,180)
Other operating receipts		-	91
<b>Total Operating Receipts</b>		<b>96,790</b>	<b>109,632</b>
<b>Operating Payments</b>			
Payments related to public fundraising		-	-
Volunteer and employee related payments	3.1	92,265	73,748
Payments related to providing goods or services	3.2	15,808	81,613
Grants and donations paid		-	-
Other operating payments		5,857	275
<b>Total Operating Payments</b>		<b>113,930</b>	<b>155,636</b>
<b>Operating Surplus or (Deficit)</b>		<b>(17,140)</b>	<b>(46,004)</b>
<b>Capital Receipts</b>			
Receipts from the sale of resources		-	-
Receipts from borrowings		-	-
<b>Capital Payments</b>			
Purchase of resources		-	-
Repayments of borrowings		-	-
<b>Increase or (decrease) in bank accounts and cash</b>		<b>(17,140)</b>	<b>(46,004)</b>
Bank accounts and cash at the beginning of the financial year		126,014	172,018
<b>Total bank accounts and cash at the end of the financial year</b>		<b>108,874</b>	<b>126,014</b>
<b>Represented by:</b>			
Bank account(s)		108,874	126,014
Term deposit(s)		-	-
Cash (including petty cash)		-	-
<b>Total Bank Accounts and Cash at the End of the Financial Year</b>		<b>108,874</b>	<b>126,014</b>

This performance report has been approved by the Executive Committee, for and on behalf of the Melanoma Network of New Zealand Incorporated:

Date 13/02/2024 13/02/2024

Signature \_\_\_\_\_

Name Gary Duncan Chris Boberg

Position Co-Chairs, MelNet Executive Committee

# Melanoma Network of New Zealand Incorporated

## Statement of Resources and Commitments

As at  
31 December 2023

SCHEDULE OF RESOURCES	This Year	Last Year
	\$126,014	\$172,018
Bank Accounts and Cash (from Statement of Receipts and Payments)	<b>126,014</b>	<b>172,018</b>
Money Held on Behalf of Others	-	-
Money Owed to the Entity	-	-
Other resources	-	-
SCHEDULE OF COMMITMENTS	This Year	Last Year
	\$0	\$0
Money Payable by the Entity	-	-
Other Commitments	-	-
Guarantees	-	-
SCHEDULE OF OTHER INFORMATION	This Year	Last Year
	\$0	\$0
Grants or donations with conditions attached	-	-
Resources used as security for borrowings	-	-
Other resources	-	-



## Melanoma Network of New Zealand Incorporated

### Notes to the Performance Report

For the year ended  
31 December 2023

#### Note 1: Accounting Policies

##### Basis of Preparation

Melanoma Network of New Zealand is permitted to apply PBE SFR-C (NFP) Public Benefit Entity Simple Format Reporting – Cash (Not-For-Profit) and has elected to do so. All transactions are reported in the Statement of Receipts and Payments and related Notes to the Performance Report on a cash basis.

##### Goods and Services Tax (GST)

Melanoma Network of New Zealand Incorporated is registered for GST. Amounts recorded in the Performance Report are GST exclusive. GST owing or GST refunds due as at balance date are shown in the Statement of Resources and Commitments.

#### Note 2: Operating Receipts

Receipt Item	Analysis	This Year \$	Last Year \$
2.1 Receipts from providing goods or services	<b>Skin Cancer Study Day for Nurses</b> Registration and sponsorship for one event (Auckland, 102 attendees). No Study Days were held in 2022 due to COVID-19.	20,307	-
	<b>Non-Melanoma Skin Cancer Seminar</b> Sponsorship and registration for one event (Auckland, 77 attendees). This was the first time this event was held.	23,884	-
	<b>Online education for health professionals</b> Sponsorship and registration for online education programme. This comprised of three online courses: Skin Cancer in the Elderly, Dermoscopy Made Easy and Non-Melanoma Skin Cancer series (2022: Quality Statements webinar series and online dermoscopy course).	34,231	33,281
	<b>Goodfellow Skin Lesion and Dermoscopy course</b> Registration fees from Goodfellow Skin Lesion and Dermoscopy course (2023: 72 attendees, held in-person in Auckland. 2022: 125 attendees, held virtually due to COVID-19)	11,530	22,773
	<b>New Zealand Melanoma Summit</b> This biennial event was not held in 2023. (2022: 189 attendees, held virtually)	-	50,972
2.2 Refund of payments for goods or services	<b>Refunds for New Zealand Melanoma Summit (due to COVID-19)</b> No Summit was held in 2023.	-	(22,180)

#### Note 3: Operating Payments

Payment Item	Analysis	This Year \$	Last Year \$
3.1 Volunteer and employee related payments	<b>Contract fee for Chief Executive</b>	60,596	48,969
	<b>Contract fee for Coordinator</b>	31,669	24,779
3.2 Payments related to providing goods or services	<b>Website</b> Website fixes, domain name renewals and web hosting subscriptions.	400	816
	<b>Goodfellow Skin Lesion and Dermoscopy course</b> Printing and travel costs. 2022 course was held online so no associated costs.	723	-
	<b>Non-Melanoma Skin Cancer Seminar</b> Travel, licences and sundry costs associated with hosting this meeting. As per 2.1, this was the first time MelNet has hosted a meeting of this kind.	3,763	-
	<b>Skin Cancer Study Day for Nurses</b> Catering, travel and other sundry costs associated with hosting the event. No Study Days were held in 2022 (as noted in 2.1)	6,555	-
	<b>Online education health professionals</b> Licences and presenter fees associated with running three online courses.	3,776	13,480
	<b>Melanoma Research and Therapy Special Interest Group meeting</b> Travel costs associated with hosting one meeting in conjunction with the NZ Society of Oncology Conference (Napier, 21 attendees)	591	-
	<b>New Zealand Melanoma Summit</b> No Summit was held in 2023.	-	67,317

#### Note 4: Correction of errors

## Melanoma Network of New Zealand Conflict of Interest Register

Last updated April 2024

The purpose of this document is to disclose and manage actual, potential or perceived conflicts of interest to protect the integrity of MelNet and manage risk.

Name	Date advised of interest	Interest disclosed	Review date
Daniel Butler	1/12/2023	Nil to declare	
Megan Chapman	30/11/2023	Nil to declare	
Amanda Oakley	3/12/2023	Speaker at MelNet events	
Amanda Oakley	3/12/2023	Speaker at Skin Cancer Symposiums	
Amanda Oakley	3/12/2023	Employee of Te Whatu Ora	
Amanda Oakley	3/12/2023	Consultant for MoleMap	
Amanda Oakley	3/12/2023	Member of NZ Dermatological Society Inc	
Gary Duncan	6/12/2023	Nil to declare	
Susan Seifried	9/12/2023	Employee of Nelson Hospital	
Abbie Cameron	15/12/2023	Employee of HealthBox	
Bronwen McNoe	15/02/2024	Employed on a programme grant funded by the Cancer Society of NZ.	
Chris Boberg	15/02/2024	President NZ Skin Cancer Doctors Society	
Chris Boberg	15/02/2024	Director Skin Cancer Symposiums	
Chris Boberg	15/02/2024	Director Skin Check Limited	
Richard Martin	12/03/2024	Board member of Melanoma NZ	
Richard Martin	12/03/2024	Board member of MASC trials	
Richard Martin	12/03/2024	Director of the Specialists Takapuna	
Richard Martin	12/03/2024	Employee of Te Whatu Ora	
Annie Wong	27/03/2024	Honorarium from Astrazeneca and Roche	
Annie Wong	27/03/2024	Executive Committee member of NZ Society of Oncology	
Annie Wong	27/03/2024	Member of Lung Oncology SIG	
Annie Wong	27/03/2024	Member of Scientific Committee for Wellington Cancer Society	
Annie Wong	27/03/2024	Member of medical oncology advisory for MASC Trials	
Annie Wong	27/03/2024	Senior Lecturer at University of Otago	
Annie Wong	27/03/2024	Research grant funding from University of Otago, NZ Society of Oncology and HRC	
Richard Massey	9/04/2024	Director and Shareholder Pathology Associates	

## Resolution for retiring Committee members to serve a further term

### Remit to AGM

#### **Background**

The Rules of MelNet state that

*“A retiring Executive Committee Member is eligible for immediate re-election but will not be eligible for more than three (3) full successive terms of two (2) years except where it has been resolved by the Executive Committee or at the Annual General Meeting that a further term or terms may be served by a retiring Executive Committee Member”*

Chris Boberg was first appointed to the MelNet Executive Committee at the inaugural general meeting in 2012. Richard Massey was first appointed at the Annual General Meeting in 2018.

Both have expressed an interest in continuing with the Committee, submitting nominations to be elected at the 2024 AGM.

#### **Proposal**

##### **Remit A:**

That a Resolution be passed for Chris Boberg and Richard Massey to be eligible for re-election to the 2024/25 Executive Committee

# Introducing the MelNet Executive Committee Members and Candidates for 2024/25

According to the Rules of the Melanoma Network of New Zealand Incorporated:

- The Executive Committee shall comprise at least 8 and no more than 15 members *“elected from amongst the Members, provided that consideration should be given to the occupations of the Members at clause 9.1 to ensure their occupations span the melanoma control continuum (prevention, diagnosis, treatment, care and research) and represent a range of disciplines”*.
- *“A retiring Executive Committee Member is eligible for immediate re-election but will not be eligible for more than 3 successive terms of 2 years except where it has been resolved by the Executive Committee or at the AGM that a further term or terms may be served by a retiring Executive Committee Member.”*

At the Annual General Meeting on 11 May 2024, members will be asked to support a maximum of ten candidates. Five committee members will be serving the second year of their two-year term.

## Candidates for election

### **Adjunct Associate Professor Amanda Oakley**

Amanda is a dermatologist at Health New Zealand (Te Whatu Ora) Waikato. She has been recognised nationally and internationally for her contribution to the field of dermatology, including being made a Companion of the New Zealand Order of Merit in the 2018 Queen's Birthday Honours. She was a founder of DermNet NZ, has authored several books, published numerous articles, and led several research trials. She also sees patients, teaches, and is actively involved in various medical organisations. Amanda is an honorary member of MelNet.

### **Dr Annie Wong**

Annie is a New Zealand-trained consultant medical oncologist at Wellington Blood and Cancer Centre. Her oncological sub-specialities include melanoma, head and neck cancer, as well as genitourinary cancers. She completed a medical oncology fellowship at Peter MacCallum Cancer Centre in Melbourne, where she was inspired by the transformative outcomes with immunotherapy and investigated novel biomarkers for melanoma immunotherapy as part of her PhD studies. She co-chairs the MelNet Melanoma Research and Therapy Special Interest Group, is on the Executive of the NZ Society of Oncology, sits on the Scientific Committee for Wellington Cancer Society and actively participates in the Australasian Melanoma and Skin Cancers Trials group. She also holds honorary positions as a clinical senior lecturer at Otago University and researcher at Peter MacCallum Cancer Centre.

### **Dr Chris Boberg**

Chris is a General Practitioner with a special interest in early detection and management of skin cancer. During his career, he has had a special interest in melanoma from a primary care perspective. Chris has been the Royal New Zealand College of General Practitioners representative on the MelNet Committee since its inception. He served as the Committee's Deputy Chair from 2012 to 2017 and has been Co-Chair over the past seven years. Chris is also chair of New Zealand Skin Cancer Doctors Society.

**Dr Keith Monnington**

Keith is a semi-retired GP with 50 years of experience in medicine, 40 years in general practice (Australia and New Zealand), 20 years in primary care skin cancer medicine (New Zealand), and 10 years as a Skin Cancer College Australasia (SCCA) Director. Currently he is the triage and grading clinician for both the Eastern and Western Bay of Plenty skin lesion services, co-ordinator for 3 online peer groups of skin cancer GPs, presenter for SCCA Certificate of Skin Cancer medicine workshop, surgical logbook assessor for the Certificate course, and tutor for the Advanced Clinical Certificate of Skin Cancer Medicine and Surgery online course. Keith has an interest in advocating for consistent funding of primary care skin cancer surgery across the country and the encouragement of best practice for the diagnosis and management of melanoma in the primary care setting in accordance with the Quality Statements.

**Dr Richard Massey**

Richard is a qualified pathologist who has been the Director of Pathology Associates for the past 17 years. Richard has a strong interest in melanocytic lesions. Richard is also on the NCSP Advisory Group and Technical Resource Group.

**Dr Sam Mayhew**

Sam is a specialist GP, Sports Doctor, Skin Cancer Doctor at Skin Institute, and a founding member of NZ Skin Cancer Doctors Society. His current leadership roles include clinical lead at his clinic, one of three skin cancer leads for his organisation, as well as being High-Performance Medical Director for Triathlon NZ and Golf NZ. Extremely passionate about melanoma, Sam works to actively raise awareness about skin cancer prevention and early detection across all his roles and platforms. He strives to make a difference and is hoping to utilise his passion towards the efforts of MelNet to help improve outcomes in an area of great importance and concern for New Zealanders.

**Dr Susan Seifried**

Susan is a General and Endoscopic surgeon based in Nelson Marlborough, where she is Head of Department of General and Vascular Surgery. She completed advanced training in General Surgery with the Royal Australasian College of Surgeons and received further specialist training as the Poche Clinical Fellow at the Melanoma Institute of Australia, Sydney under the guidance of eminent General, Breast and Plastic Surgeons. Susan is the current Chair of the National Melanoma Working Group responsible for maintaining the Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand. She is a Fellow of the Royal Australasian College of Surgeons, a member of the NZ Association of General Surgeons, BreastSurgANZ and has accreditation for colonoscopy and gastroscopy by the New Zealand Conjoint Committee.

**Mr Dan Butler**

Dan Butler is a specialist plastic and reconstructive surgeon with a subspecialty interest in melanoma and head and neck cancer. Dan took up his role at Tauranga Hospital in 2021 having moved from his NHS consultant post at Queen Victoria Hospital in the UK. During his training in the UK, Dan had the opportunity to work in some of the largest tertiary referral centres for skin cancer management along with undertaking fellowship training within skin cancer and head and neck surgery. Dan recently lead the process to establish a dedicated skin cancer MDM within the Bay of Plenty and currently acts as the Chairperson for the weekly meeting.

**Committee members to serve a second year**

- **Abbie Cameron** (Nurse, Christchurch)
- **Dr Bronwen McNoe** (Prevention Researcher, Dunedin)
- **Mr Gary Duncan** (Plastic Surgeon, Hawke's Bay)
- **Dr Jody Jordan** (Medical Oncologist, Hawke's Bay)
- **Mr Richard Martin** (Surgical Oncologist, Auckland)